- Theragnostics’ novel PET tracer, GalliProst, will help visualize prostate cancer to enable personalized treatment.
- The two companies will leverage their combined scientific, commercial and market access expertise to work towards a commercial launch.
Chalfont St Giles, UK – October 9th 2019 – GE Healthcare and Theragnostics have entered into a global commercial partnership for a new Prostate-Specific Membrane Antigen (PSMA) PET/CT imaging agent.
For media inquiries, please contact:
David MorrisCommunications Director, Pharmaceutical Diagnostics
GE Healthcare
+44 7920591370
David.J.Morris@ge.com
Europe/London